Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation ; day:18 ; month:10 ; year:2023 ; pages:1-7
Clinical and translational oncology ; (18.10.2023), 1-7
- Creator
-
Bueno, Maria Jose
Mouron, Silvana
Caleiras, Eduardo
Martínez, Mario
Manso, Luis
Colomer, Ramón
Quintela-Fandino, Miguel
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12094-023-03329-9
- URN
-
urn:nbn:de:101:1-2024010809380888173904
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bueno, Maria Jose
- Mouron, Silvana
- Caleiras, Eduardo
- Martínez, Mario
- Manso, Luis
- Colomer, Ramón
- Quintela-Fandino, Miguel
- SpringerLink (Online service)
Other Objects (12)
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Real de-escalation or escalation in disguise?
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Real de-escalation or escalation in disguise?
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Real de-escalation or escalation in disguise?